146 related articles for article (PubMed ID: 29131561)
21. A forensic analysis of drug targets from 2000 through 2012.
Munos B
Clin Pharmacol Ther; 2013 Sep; 94(3):407-11. PubMed ID: 23756372
[TBL] [Abstract][Full Text] [Related]
22. An improved approach to measuring drug innovation finds steady rates of first-in-class pharmaceuticals, 1987-2011.
Lanthier M; Miller KL; Nardinelli C; Woodcock J
Health Aff (Millwood); 2013 Aug; 32(8):1433-9. PubMed ID: 23918488
[TBL] [Abstract][Full Text] [Related]
23. Medicine, pharmacy, and industry--a fly's eye view of health care.
Halperin JA
Ann Pharmacother; 1995 Sep; 29(9):925-33. PubMed ID: 8547743
[No Abstract] [Full Text] [Related]
24. Muddied messages about FDA.
Miller HI
Nat Biotechnol; 2003 Jul; 21(7):732-3. PubMed ID: 12833084
[No Abstract] [Full Text] [Related]
25. The contribution of pharmaceutical companies: what's at stake for America. Executive summary from a report prepared by the Boston Consulting Group.
Broshy E
Ann N Y Acad Sci; 1994 Nov; 729():111-26; discussion 139-42. PubMed ID: 7998722
[No Abstract] [Full Text] [Related]
26. Increases in Drug Spending Slow.
State Legis; 2017 Apr; 43(4):6. PubMed ID: 28574682
[No Abstract] [Full Text] [Related]
27. Pharmacoeconomics: the new dismal science.
Luchins DJ
Adm Policy Ment Health; 2004 May; 31(5):425-7. PubMed ID: 15379388
[No Abstract] [Full Text] [Related]
28. Proposal To Use VA Price As a Benchmark Is off the Mark.
Kirkner RM
Manag Care; 2016 Dec; 25(12):14-15. PubMed ID: 28121548
[TBL] [Abstract][Full Text] [Related]
29. New drug approvals for 2002.
Frantz S; Smith A
Nat Rev Drug Discov; 2003 Feb; 2(2):95-6. PubMed ID: 12572538
[No Abstract] [Full Text] [Related]
30. What's the benefit? A new federal Medicare drug plan stimulates independent actions and new ideas, but what's the future role for states?
Cauchi R
State Legis; 2004; 30(7):28-33. PubMed ID: 15241878
[No Abstract] [Full Text] [Related]
31. Pharmaceutical research: cost savings through innovation.
Cohen KR; Levy RA
AAPPO J; 1993 Oct; 3(5):28-36. PubMed ID: 10146463
[No Abstract] [Full Text] [Related]
32. [Fewer new drugs from drug industry].
Reikvam A
Tidsskr Nor Laegeforen; 2007 Nov; 127(23):3106-7. PubMed ID: 18049505
[No Abstract] [Full Text] [Related]
33. BIG INNOVATION IN SMALL PLACES.
Alsever J
Fortune; 2016 Jun; 173(7):29-30. PubMed ID: 27491136
[No Abstract] [Full Text] [Related]
34. Burden of prescription drug costs in the United States.
Curtiss FR
J Manag Care Pharm; 2003; 9(1):91-2. PubMed ID: 14613372
[No Abstract] [Full Text] [Related]
35. Settlements between brand and generic pharmaceutical companies: a reasonable antitrust analysis of reverse payments.
Yvon AM
Fordham Law Rev; 2006 Dec; 75(3):1883-912. PubMed ID: 17312596
[No Abstract] [Full Text] [Related]
36. Projecting future drug expenditures--1998.
Mehl B; Santell JP
Am J Health Syst Pharm; 1998 Jan; 55(2):127-36. PubMed ID: 9465976
[TBL] [Abstract][Full Text] [Related]
37. US FDA's safety monitoring of drugs with expedited approval.
Furlow B
Lancet Oncol; 2016 Mar; 17(3):281. PubMed ID: 26831290
[No Abstract] [Full Text] [Related]
38. A merger too far?
Wadman M
Nature; 2007 Mar; 446(7131):15. PubMed ID: 17330017
[No Abstract] [Full Text] [Related]
39. Benchmarking biotech and pharmaceutical product development.
Drakeman DL
Nat Biotechnol; 2014 Jul; 32(7):621-5. PubMed ID: 25004226
[No Abstract] [Full Text] [Related]
40. Prospects for productivity.
Booth B; Zemmel R
Nat Rev Drug Discov; 2004 May; 3(5):451-6. PubMed ID: 15136792
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
